Compare Invesco Ltd. (IVZ) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco Ltd. vs Organon & Co. Common Stock — how do they compare? Invesco Ltd. trades at $27.87 (market cap $12.77B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Invesco Ltd. is far larger — about 3.5× Organon & Co. Common Stock's market cap, and Invesco Ltd. pays the higher dividend (2.97%). Which is the better fit depends on your goals — on Pluang, investors hold Invesco Ltd. for 77 Days and Organon & Co. Common Stock for 0 Days on average.
| IVZ | OGN | |
|---|---|---|
Market Cap | $12.77B | $3.62B |
Volume | 2,758,656 | 2,892,999 |
Sector | Financials | Health |
52-Week High | $33.31 | $13.81 |
52-Week Low | $22.44 | $5.70 |
Typical Hold Time | 77 Days | 0 Days |
Enterprise Value | $22.93B | $11.04B |
Dividend Yield | 2.97% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Invesco (IVZ) trades at $28.92, down 1.16% with bearish technical signals despite recent earnings beats. The company shows mixed fundamentals with revenue growth to $6.38B in 2025 but negative net margins of -0.93%. Analyst consensus remains cautiously optimistic with a $33.17 price target and no sell ratings, while technical indicators suggest near-term pressure with support at $28.
Investment outlook balances strong asset growth momentum (AUM up 4.7% to $2.56T in August 2026) against profitability challenges. Key opportunities include dividend yield and ETF expansion, while risks center on margin pressure and market volatility. The stock presents value potential if operational improvements materialize.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Invesco Ltd.
Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).
Read more on IVZ →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
